News

CURE10h
First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer
The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...
BC Technology11h
Zucara Therapeutics Announces Second and Final Closing of US $25 Million Series-B Financing (with Additional US $5 Million)
Zucara Therapeutics Inc., a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent ...